Document Detail

Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
MedLine Citation:
PMID:  15942707     Owner:  NLM     Status:  MEDLINE    
The use of beta-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1alpha (HIF-1alpha) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1alpha in cardiac hypertrophy due to pressure overload and after treatment with beta-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1alpha expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 +/- 9 mmHg in the sham group to 94 +/-5 mmHg (p < 0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1alpha, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-beta (NGF-beta) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1alpha, VEGF and BNP increased and mRNA of NGF-beta decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values. Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1alpha, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-beta mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP, and NGF-beta in the hypertrophic myocardium.
Kou-Gi Shyu; Jer-Young Liou; Bao-Wei Wang; Wei-Jen Fang; Hang Chang
Related Documents :
8874137 - U50,488h-induced pressor effect in the ovine foetus is mediated by sympathetic activati...
22424547 - Effects of the time of antihypertensive drugs administration on the stage of primary op...
3227947 - Positive inotropic effect on the rat atrial myocardium compressed to 5, 10 and 30 bar.
3192847 - Propranolol blocks ventricular refractory period changes with orthostatic stress in hum...
22348547 - Noninvasive positive pressure ventilation for post-pneumonectomy severe hypoxemia: a ca...
23009907 - Pulmonary hypertension and right ventricular dysfunction in left heart disease (group 2...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of biomedical science     Volume:  12     ISSN:  1021-7770     ISO Abbreviation:  J. Biomed. Sci.     Publication Date:  2005  
Date Detail:
Created Date:  2005-06-08     Completed Date:  2005-09-23     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9421567     Medline TA:  J Biomed Sci     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  409-20     Citation Subset:  IM    
Department of Education and Research, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wen-Chang Rd, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetylcysteine / pharmacology
Antihypertensive Agents / pharmacology
Aorta / pathology
Arteries / pathology
Blotting, Western
Body Weight
Carbazoles / pharmacology*
Doxazosin / pharmacology
Hypertrophy / pathology*
Hypoxia-Inducible Factor 1, alpha Subunit
Myocardium / pathology*
Nerve Growth Factor / metabolism
Organ Size
Propanolamines / pharmacology*
RNA, Messenger / metabolism
Rats, Sprague-Dawley
Reverse Transcriptase Polymerase Chain Reaction
Tetrazoles / pharmacology
Transcription Factors / metabolism*
Valine / analogs & derivatives,  pharmacology
Vascular Endothelial Growth Factor A / metabolism*
Vasodilator Agents / pharmacology
Reg. No./Substance:
0/Antihypertensive Agents; 0/Carbazoles; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/Propanolamines; 0/RNA, Messenger; 0/Tetrazoles; 0/Transcription Factors; 0/Vascular Endothelial Growth Factor A; 0/Vasodilator Agents; 0K47UL67F2/carvedilol; 137862-53-4/valsartan; 616-91-1/Acetylcysteine; 7004-03-7/Valine; 74191-85-8/Doxazosin; 9061-61-4/Nerve Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neuropeptide Y and its receptor analogs differentially modulate the immunoreactivity for neuronal or...
Next Document:  Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for ...